SCHEMBL29319329

SCHEMBL29319329

CC(C)(C)OC(=O)N1CCC(c2cc3nn(COCC[Si](C)(C)C)cc3s2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.40
MAPT P10636 3/20 0.40
THRB P10828 2/20 0.40
KLKB1 P03952 1/20 0.39
TP53 P04637 2/20 0.38
SYK P43405 1/20 0.38
HTT P42858 2/20 0.38
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
TSHR P16473 2/20 0.38
KMT2A Q03164 2/20 0.38
HSD17B10 Q99714 2/20 0.38
GAA P10253 2/20 0.38
USP2 O75604 1/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CRHBP P24387 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31433908 0.81 GPR119 (0.41) KDM4EMAPTTHRBTP53HTT
SCHEMBL25306093 0.81 MAPT (0.42) KDM4EMAPTTHRBTP53HTT
SCHEMBL20440617 0.80 HPGD (0.41) KDM4EMAPTTHRBTP53SYK
SCHEMBL29319317 0.79 KIT (0.44) NAMPTGPR119
SCHEMBL30926359 0.78 SMN1; SMN2 (0.43) KDM4EMAPTTHRBHTTMEN1
SCHEMBL31434010 0.76 CNR1 (0.42) KDM4EMAPTHTTMEN1ALDH1A1
SCHEMBL30447419 0.75 CHRM2 (0.35) KLKB1GPR119
SCHEMBL30926199 0.74 KDM4E (0.44) KDM4EMAPTTHRBHTTMEN1
SCHEMBL30926207 0.73 KDM4E (0.41) KDM4EMAPTTHRBHTTMEN1
SCHEMBL25308464 0.73 ALOX5AP (0.35) KDM4EMAPTKLKB1SMN1; SMN2NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239811-A1 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T REMIX THERAPEUTICS INC. 2024-07-18 US disclosed
WO-2023133229-A2 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-07-13 WO disclosed
EP-4178963-A1 5-[5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES Remix Therapeutics Inc. (US) 2023-05-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239811-A1 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T HNRNPAB, HNRNPC, HNRNPA1 KDM4E 2019/4885MAPT 2035/4885THRB 1340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.